Sunshine Biopharma
SBFM
9 hedge funds and large institutions have $32.6K invested in Sunshine Biopharma in 2026 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 5 closing their positions.
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
13% more funds holding
Funds holding: 8 → 9 (+1)
0.67% more ownership
Funds ownership: 2.49% → 3.17% (+0.67%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
74% less capital invested
Capital invested by funds: $127K → $32.6K (-$94.5K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$95.9K |
| 2 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$26 |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$13 |
| 4 |
CIAM
Caitong International Asset Management
Hong Kong
|
+$6 |
| 5 |
FFA
Farther Finance Advisors
San Francisco,
California
|
+$6 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$48.1K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$24.4K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$22.3K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$14K |
| 5 |
Morgan Stanley
New York
|
-$6.91K |
SBFM Hedge Fund Activity: Q2 2026 in Review
9 of the 8,329 institutional investors tracked by Wall St. Rank reported a position in Sunshine Biopharma (SBFM) for Q2 2026, worth a combined $32.6K — down 74% from $127K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new SBFM positions and 5 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $95.9K. The largest seller was Citadel Advisors, exiting entirely with an estimated $48.1K sold.
- 9 institutional investors held Sunshine Biopharma (SBFM) as of Q2 2026, up from 8 in Q1 2026.
- Funds reported $32.6K of Sunshine Biopharma stock for Q2 2026, down 74% quarter-over-quarter.
- 6 funds opened new Sunshine Biopharma positions in Q2 2026 and 5 closed out, a net change of +1 holder.
- The largest Sunshine Biopharma buyer in Q2 2026 was Jane Street, an estimated $95.9K added.
- The largest Sunshine Biopharma seller in Q2 2026 was Citadel Advisors, an estimated $48.1K sold.
Based on aggregated 13F filings for Q2 2026.